Bovhyaluronidase azoximer

阿佐西姆牛透明质酸酶

Report date: 2024/04/26 17:20:12

Base Information

Drug NameBovhyaluronidase azoximer
Drug Alias NameLongidazeLongidaza®
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionHyaluronidase stimulants
TargetsHyaluronidase
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeHyperplasiaFibrosis +[7] 
Global Approved IndicationsHyperplasia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2005/12/01
Country/TerritoryUzbekistanRussian Federation
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPetrovax Pharma
China Registration ClassN/A

Develop Information

Active CompaniesNpo PetrovaxPetrovax Pharma
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromeHyperplasiaFibrosis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeB06AA03
Related LinksN/A